An integrative bioinformatics analysis identified miR-375 as a candidate key regulator of malignant breast cancer

Liu, Jiaxuan; Wang, Ping; Zhang, Ping; Zhang, Xinyu; Du, Hang; Liu, Qiang; Huang, Bo; Qian, Caiyun; Zhang, Shuhua; Zhu, Weixing; Yang, Xiaohong; Xiao, Ying-Qun; Liu, Kebin; Luo, Daya

doi:10.1007/s13353-019-00507-w

Cited by 32 publications

(31 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially, we noted a downregulation of miR-375 in cervical cancer, whereas its upregulation could attenuate cervical cancer cell proliferation, migration, and invasion, while triggering cell apoptosis in vitro. The downregulation of miR-375 has been commonly found in multiple cancers, including colorectal cancer [ 21 ], ovarian cancer [ 22 ], and breast cancer [ 23 ]. Moreover, miR-375 expression was shown to be significantly reduced in cervical cancer cells, while its ectopic expression suppressed cervical cancer cell proliferation, migration, invasion, and angiogenesis and increased the 5-fluorouracil-induced apoptosis [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: microRNA-375 released from extracellular vesicles of bone marrow mesenchymal stem cells exerts anti-oncogenic effects against cervical cancer

2020

View full text Add to dashboard Cite

Background Cervical cancer is the most prevalent gynecological malignancies accompanied by high mortality, where finding a more effective therapeutic option for cervical cancer is necessary. The inhibitory role of microRNAs (miRNAs) derived from the extracellular vesicles (EVs) of the bone marrow mesenchymal stem cells (BMSCs) was analyzed in cervical cancer. Methods Expression of miR-375 was examined by RT-qPCR in cervical cancer cell lines. The targeting relation between miR-375 and maternal embryonic leucine zipper kinase (MELK) was predicted by bioinformatics analysis and verified by dual-luciferase reporter gene assay. Isolated BMSCs were transfected with lentivirus-mediated vectors, followed by EV extraction. The morphology of EVs was then identified using a NanoSight particle size analyzer and transmission electron microscope (TEM). The biological properties of cervical cancer cells were evaluated using Transwell, EdU, and TUNEL assays, respectively. Xenograft tumors in nude mice were observed to assess cervical tumorigenesis in vivo. Results Low expression of miR-375 and high expression of MELK were detected in cervical cancer samples. MELK was identified as the target gene of miR-375, which was negatively correlated with miR-375 levels. Overexpression of miR-375 suppressed proliferation, migration, and invasion of cervical cancer cells, but enhanced cell apoptosis by cooperating with downregulated MELK expression. miR-375 transferred from BMSC-derived EVs exerted the same effects on cell biological activities. Xenograft assays in vivo proved that miR-375 from BMSC-derived EVs inhibited tumor growth. Conclusion The present study highlighted the role of miR-375 from BMSC-derived EVs in suppressing the progression of cervical cancer, which may contribute to the discovery of novel potential biomarkers for cervical cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: microRNA-375 released from extracellular vesicles of bone marrow mesenchymal stem cells exerts anti-oncogenic effects against cervical cancer

2020

View full text Add to dashboard Cite

show abstract

“…These data indicated that eIF5A could be an effective target for breast cancer therapy. Liu et al ( 93 ) reported that eIF5A2 was identified as a candidate target gene of miR-375, which was suggested to serve as a tumor suppressor in breast cancer. However, to the best of our knowledge, the expression of eIF5A in breast cancer tissues and its association with the clinicopathology of patients with breast cancer have not been reported.…”

Section: Role Of Eif5a In Malignant Tumorsmentioning

confidence: 99%

Eukaryotic translation initiation factor 5A in the pathogenesis of cancers (Review)

et al. 2020

View full text Add to dashboard Cite

Cancer is the leading cause of death worldwide. The absence of obvious symptoms and insufficiently sensitive biomarkers in early stages of carcinoma limits early diagnosis. Cancer therapy agents and targeted therapy have been used extensively against tissues or organs of specific cancers. However, the intrinsic and/or acquired resistance to the agents or targeted drugs as well as the serious toxic side effects of the drugs would limit their use. Therefore, identifying biomarkers involved in tumorigenesis and progression represents a challenge for cancer diagnosis and therapeutic strategy development. The eukaryotic translation factor 5A (eIF5A), originally identified as an initiation factor, was later shown to promote translation elongation of iterated proline sequences. There are two eIF5A isoforms (eIF5A1 and eIF5A2). eIF5A2 protein consists of 153 residues, and shares 84% amino acid identity with eIF5A1. However, the biological functions of these two isoforms may be significantly different. Recently, it was demonstrated that eIF5Ais widely involved in the pathogenesis of a number of diseases, including cancers. In particular, eIF5A plays an important role in regulating tumor growth, invasion, metastasis and tumor microenvironment. It was also shown to serve as a potential biomarker and target for the diagnosis and treatment of cancers. The present review briefly discusses the latest findings of eIF5A in the pathogenesis of certain malignant cancers and evolving clinical applications.

show abstract

“…MicroRNAs (miRNAs) belong to the family of non-coding RNAs with 20-24 nucleotides in length. Usually, miRNAs can silence the target genes by post-transcriptional regulation by binding to the 3 untranslated region (UTR) of target genes [6], and dysregulation of the miRNAs has been proved to have significant correlation with tumor initiation, progression and metastasis [7][8][9][10]. MiR-139-5p, located on chromosome 11q13.4, takes part in many important signaling pathway and has been showed to play anti-oncogenic roles in many cancers [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

MiR-139-5p influences hepatocellular carcinoma cell invasion and proliferation capacities via decreasing SLITRK4 expression

et al. 2020

View full text Add to dashboard Cite

The microRNA, miR-139-5p, has been proved to play important roles in regulating tumor progression, including prostate cancer, osteosarcoma, esophageal cancer, and so on, but its correlation of hepatocellular carcinoma (HCC) still remains unclear. Here we found that hsa-miR-139-5p (miR-139-5p) was decreased in HCC samples compared with normal liver tissues, and a lower expression of miR-139-5p was connected to a poorer prognosis. Mechanism study indicated that a decreased/increased miR-139-5p could increase/decrease HCC cells invasion and proliferation capacities via increasing SLITRK4 expression, what’s more, the reverse assays also confirmed the conclusion when we knocked down SLITRK4 in the miR-139-5p low-expression cells. Luciferase assay confirmed that miR-139-5p could directly bind to the 3′UTR of SLITRK4 mRNA to regulate its expression. Together, these findings show the importance of miR-139-5p/SLITRK4 pathway in HCC growth and progression and may provide new targets for us to better arrange the progression of HCC.

show abstract

An integrative bioinformatics analysis identified miR-375 as a candidate key regulator of malignant breast cancer

Cited by 32 publications

References 72 publications

RETRACTED ARTICLE: microRNA-375 released from extracellular vesicles of bone marrow mesenchymal stem cells exerts anti-oncogenic effects against cervical cancer

RETRACTED ARTICLE: microRNA-375 released from extracellular vesicles of bone marrow mesenchymal stem cells exerts anti-oncogenic effects against cervical cancer

Eukaryotic translation initiation factor 5A in the pathogenesis of cancers (Review)

MiR-139-5p influences hepatocellular carcinoma cell invasion and proliferation capacities via decreasing SLITRK4 expression

Contact Info

Product

Resources

About

An integrative bioinformatics analysis identified miR-375 as a candidate key regulator of malignant breast cancer

Cited by 32 publications

References 72 publications

RETRACTED ARTICLE: microRNA-375 released from extracellular vesicles of bone marrow mesenchymal stem cells exerts anti-oncogenic effects against cervical cancer

RETRACTED ARTICLE: microRNA-375 released from extracellular vesicles of bone marrow mesenchymal stem cells exerts anti-oncogenic effects against cervical cancer

Eukaryotic translation initiation factor&nbsp;5A in the pathogenesis of cancers (Review)

MiR-139-5p influences hepatocellular carcinoma cell invasion and proliferation capacities via decreasing SLITRK4 expression

Contact Info

Product

Resources

About

Eukaryotic translation initiation factor 5A in the pathogenesis of cancers (Review)